Deniz Publication
Clinical Cancer Investigation Journal
ISSN Print: 2278-1668, Online: 2278-0513


Publisher: Deniz Publication
ARTICLE
Year: 2014   |   Volume: 3   |   Issue: 5   |   Page: 401-404     View issue

Primary parotid B-cell lymphoma successfully treated with chemotherapy plus highly active antiretroviral therapy with prolonged survival and immune reconstitution in an acquired immunodeficiency syndrome patient: Case report and review of the literature


, ,
Abstract

Non-Hodgkin′s lymphoma (NHL) is the second most common acquired immunodeficiency syndrome (AIDS)-defining cancer. In this population, up to 70-80% of cases may present as extranodal location as the primary clinical manifestation of the neoplasm disease. Gastrointestinal tract is the most frequent location of AIDS-associated NHL. However, salivary gland involvement, including the parotid gland is a rare complication in human immunodeficiency virus (HIV)-patients. Here, we describe a patient seropositive for the HIV, who developed a primary NHL of the parotid gland histologically classified as a high-grade diffuse large B-cell lymphoma. Patient was treated with a combination of chemotherapy plus highly active antiretroviral therapy with a good clinical, virological and immunological response and a prolonged survival, more than 5 years, without evidence of neoplasm relapse.

Cite this article
Vancouver
Corti M, Bistmans A, Narbaitz M. Primary parotid B-cell lymphoma successfully treated with chemotherapy plus highly active antiretroviral therapy with prolonged survival and immune reconstitution in an acquired immunodeficiency syndrome patient: Case report and review of the literature. Clin Cancer Investig J. 2014;3(5):401-4. https://doi.org/10.4103/2278-0513.138062
APA
Corti, M., Bistmans, A., & Narbaitz, M. (2014). Primary parotid B-cell lymphoma successfully treated with chemotherapy plus highly active antiretroviral therapy with prolonged survival and immune reconstitution in an acquired immunodeficiency syndrome patient: Case report and review of the literature. Clinical Cancer Investigation Journal, 3(5), 401-404. https://doi.org/10.4103/2278-0513.138062

Copyright © 2024 Clinical Cancer Investigation Journal. Authors retain copyright of their article if they are accepted for publication.
Creative Commons License 
ISSN Print: 2278-1668, Online: 2278-0513